Phase 1 Single and Multiple Ascending Dose Study in Males and Females Assessing the Pharmacokinetics, Safety, and Pharmacodynamics of HS235 in Overweight and Obese Otherwise Healthy Subjects
Latest Information Update: 11 Dec 2024
At a glance
- Drugs HS 235 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors 35Pharma
Most Recent Events
- 11 Dec 2024 New trial record